Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.50 |
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | ADA | P00813 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23852703 | 0.85 | ADORA2A (0.47) | ADORA2A | |
| SCHEMBL23854169 | 0.82 | ADORA2A (0.49) | ADORA2AHPGDSUSP30EGFRSRC | |
| SCHEMBL23854170 | 0.82 | ADORA2A (0.49) | ADORA2AHPGDSUSP30EGFRSRC | |
| SCHEMBL5788417 | 0.76 | HPGDS (0.52) | HPGDSUSP30CKS1BSKP1SKP2 | |
| SCHEMBL24129963 | 0.76 | HPGDS (0.42) | ADORA2AHPGDSUSP30CKS1BSKP1 | |
| SCHEMBL23854156 | 0.75 | HPGDS (0.42) | ADORA2AHPGDSUSP30CKS1BSKP1 | |
| SCHEMBL23854157 | 0.75 | HPGDS (0.42) | ADORA2AHPGDSUSP30CKS1BSKP1 | |
| SCHEMBL23854155 | 0.75 | HPGDS (0.42) | ADORA2AHPGDSUSP30CKS1BSKP1 | |
| SCHEMBL4226659 | 0.75 | HSD11B1 (0.62) | HPGDSUSP30 | |
| SCHEMBL14051086 | 0.74 | CHEK1 (0.50) | HPGDSUSP30CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883575-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2021-09-29 | — | — | EP | disclosed |